Allergan shifts sales reps to Botox for its new indication by ProQuest


Allergan sales forces previously working on GlaxoSmithKline headache drugs Imitrex and Amerge as part of a co-promotion will be reassigned to Botox, in support of the drug's new headache indication. Crystal Muilenburg, a spokesperson for Allergan, told MM&M that sales forces will initially target neurologists, pain and headache specialists, to train them on Botox's injection protocol and dosing regimen. A key challenge that they started addressing immediately upon FDA approval is reimbursement. Allergan paid $600 million to settle Justice Department charges of off-label marketing in September.

More Info
To top